Abstract
Malignant melanoma is highly aggressive, and always resistant to conventional chemo-radiotherapy, which results in poor prognosis. As a specific antagonist of neurotensin receptor 1 (NTSR1), emerging evidences confirmed that SR48692 can reverse the pro-growth effect of neurotensin (NTS) by interrupting the interaction between NTS and NTSR1. A375 melanoma cell line was used in this experiment, and SR48692 was employed as the inhibitor of NTS/NTSR1 pathway. We detected the expression of NTSR1 by NTSR1 immunofluorescence and Western blot. After SR48692 treatment, cell proliferation was determined by cell counting, MTT assay and BrdU incorporation study, the cell cycle and apoptosis were performed by flow cytometry. At last Soft Agar Clonogenic assay and xenograft cancer mice model in vivo were used to confirm our result. In this study, we showed that NTSR1 is commonly high expressed in melanoma cells, but low expressed in normal immortalized human keratinocyte line HaCaT. SR48692 not only reduced cell proliferation and self-renewal potential in vitro, but also inhibited the tumor growth derived from A375 cells in NOD/SCID mice in vivo. Further, we originally reported that SR48692 inhibited cell proliferation through cell cycle arr...Continue Reading
References
Mar 1, 1992·Human Pathology·P A di Sant'Agnese
Oct 11, 1992·Annals of Surgery·B M EversJ C Thompson
Feb 28, 1989·European Journal of Pharmacology·T P DavisR H Liu
May 6, 1985·Life Sciences·T W MoodyJ D Minna
Mar 10, 1984·Lancet·N A CollierL H Blumgart
May 24, 1994·Proceedings of the National Academy of Sciences of the United States of America·I SehgalN J Maihle
Jan 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·D GullyA Brouard
Jan 1, 1995·Fundamental & Clinical Pharmacology·D GullyJ P Maffrand
May 1, 1997·Cancer·K IwaseC M Townsend
Oct 1, 1996·Surgical Oncology·K IwaseC M Townsend
Apr 24, 1997·Annals of the New York Academy of Sciences·W RosteneD Gully
May 15, 1997·The Prostate·L SeethalakshmiR E Carraway
Aug 1, 1997·Progress in Neurobiology·T Jolas, G K Aghajanian
Feb 6, 1999·International Journal of Cancer. Journal International Du Cancer·J J MaoretM Laburthe
Jul 2, 1999·International Journal of Cancer. Journal International Du Cancer·J C ReubiJ A Laissue
Apr 17, 2001·International Journal of Cancer. Journal International Du Cancer·C Dal FarraJ P Vincent
Jun 13, 2003·Life Sciences·Paul R DobnerJim Fadel
Jun 17, 2006·Cancer Research·Frédérique SouazéPatricia Forgez
Jul 4, 2006·Neuroscience·L ChenW H Yung
Aug 30, 2008·Brain Research Bulletin·Polina Petkova-KirovaAliz Mayer
Oct 7, 2008·Neurochemistry International·Polina Petkova-KirovaAnikó Vágvölgyi
Sep 3, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marco AlifanoPatricia Forgez
May 25, 2011·Biochimie·Sandra DupouyPatricia Forgez
Citations
May 31, 2017·Clinical and Experimental Pharmacology & Physiology·Qing OuyangLiang Yi
Feb 23, 2018·Oncotarget·Jan KorbeckiIrena Baranowska-Bosiacka
Feb 3, 2018·Oncology Letters·Huajia DaiSong Zhu
May 12, 2017·British Journal of Cancer·Zhen DongLiang Yi
Nov 21, 2018·PloS One·Michelle L MaughamLisa K Chopin
Feb 26, 2015·Frontiers in Pharmacology·Hee-Kyoung LeeGrzegorz Bulaj
Nov 1, 2016·International Reviews of Immunology·Yingnan YeJinpu Yu
Oct 10, 2020·Molecular Oncology·Kei TakahashiKohei Miyazono
Aug 10, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jin LiuPatricia Forgez
Jan 24, 2021·Cell Death & Disease·Yanli ZhangHongjuan Cui
Apr 28, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Tao HouXinmiao Liang
May 12, 2021·Bioinformatics·Jon E T JakobssonMalin C Lagerström
Oct 2, 2021·Breast Cancer Research and Treatment·Clément MorgatElif Hindié